{
    "Clinical Trial ID": "NCT00080301",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Ixabepilone + Capecitabine",
        "  Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each 21-day cycle, plus oral capecitabine 1000 mg/m2 twice a day (BID) x 14 days",
        "INTERVENTION 2: ",
        "  Capecitabine",
        "  Capecitabine 1250 mg/m2 BID x 14 days"
    ],
    "Eligibility": [
        "Patients must have received either 2 or 3 prior chemotherapy regimens including adjuvant or neoadjuvant therapy.",
        "  Prior treatment must have included both an anthracycline (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel).",
        "  Patients must have received a minimum cumulative dose of anthracycline or must be resistant to an anthracycline.",
        "  Patients must be resistant to taxane therapy.",
        "  Patients may not have any history of brain and/or leptomeningeal metastases.",
        "  Patients may not have CTC Grade 2 or greater neuropathy (motor or sensory).",
        "  Patients may have not have had prior treatment with an epothilone and/or capecitabine (i.e., Xeloda)"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression-free Survival (PFS) Per Independent Radiology Review Committee (IRRC)",
        "  PFS defined as the time in months from randomization to date of progression. Patients who died without a reported prior progression were considered to have progressed on date of death; those who didn't progress or die were censored on date of last tumor assessment. Median PFS time with 95% CI estimated using the Kaplan Meier product limit method.",
        "  Time frame: based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity",
        "Results 1: ",
        "  Arm/Group Title: Ixabepilone + Capecitabine",
        "  Arm/Group Description: Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each 21-day cycle, plus oral capecitabine 1000 mg/m2 twice a day (BID) x 14 days",
        "  Overall Number of Participants Analyzed: 375",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  5.85        (5.45 to 6.97)",
        "Results 2: ",
        "  Arm/Group Title: Capecitabine",
        "  Arm/Group Description: Capecitabine 1250 mg/m2 BID x 14 days",
        "  Overall Number of Participants Analyzed: 377",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  4.17        (3.81 to 4.50)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 127/368 (34.51%)",
        "  ANAEMIA 3/368 (0.82%)",
        "  LEUKOPENIA 0/368 (0.00%)",
        "  NEUTROPENIA 0/368 (0.00%)",
        "  COAGULOPATHY 3/368 (0.82%)",
        "  LYMPHADENOPATHY 0/368 (0.00%)",
        "  THROMBOCYTOPENIA 2/368 (0.54%)",
        "  BONE MARROW FAILURE 0/368 (0.00%)",
        "  FEBRILE NEUTROPENIA 4/368 (1.09%)",
        "  DISSEMINATED INTRAVASCULAR COAGULATION 0/368 (0.00%)",
        "  ATRIAL FLUTTER 0/368 (0.00%)",
        "  CARDIAC ARREST 0/368 (0.00%)",
        "Adverse Events 2:",
        "  Total: 151/369 (40.92%)",
        "  ANAEMIA 11/369 (2.98%)",
        "  LEUKOPENIA 6/369 (1.63%)",
        "  NEUTROPENIA 18/369 (4.88%)",
        "  COAGULOPATHY 0/369 (0.00%)",
        "  LYMPHADENOPATHY 1/369 (0.27%)",
        "  THROMBOCYTOPENIA 7/369 (1.90%)",
        "  BONE MARROW FAILURE 1/369 (0.27%)",
        "  FEBRILE NEUTROPENIA 15/369 (4.07%)",
        "  DISSEMINATED INTRAVASCULAR COAGULATION 1/369 (0.27%)",
        "  ATRIAL FLUTTER 1/369 (0.27%)",
        "  CARDIAC ARREST 1/369 (0.27%)"
    ]
}